Editas Medicine (EDIT) Competitors $1.58 +0.08 (+5.00%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT vs. STOK, RLAY, TSHA, MNMD, UPB, DNA, URGN, ETON, ARVN, and CGEMShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Stoke Therapeutics (STOK), Relay Therapeutics (RLAY), Taysha Gene Therapies (TSHA), Mind Medicine (MindMed) (MNMD), Upstream Bio (UPB), Ginkgo Bioworks (DNA), UroGen Pharma (URGN), Eton Pharmaceuticals (ETON), Arvinas (ARVN), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. Stoke Therapeutics Relay Therapeutics Taysha Gene Therapies Mind Medicine (MindMed) Upstream Bio Ginkgo Bioworks UroGen Pharma Eton Pharmaceuticals Arvinas Cullinan Therapeutics Editas Medicine (NASDAQ:EDIT) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has preferable earnings and valuation, EDIT or STOK? Stoke Therapeutics has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$35.84M3.50-$153.22M-$3.04-0.49Stoke Therapeutics$190.91M2.71-$104.70M$0.7912.00 Do analysts rate EDIT or STOK? Editas Medicine presently has a consensus target price of $5.36, indicating a potential upside of 257.58%. Stoke Therapeutics has a consensus target price of $23.20, indicating a potential upside of 144.73%. Given Editas Medicine's higher possible upside, analysts plainly believe Editas Medicine is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 2 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.29Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more risk & volatility, EDIT or STOK? Editas Medicine has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Does the MarketBeat Community prefer EDIT or STOK? Editas Medicine received 196 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 76.58% of users gave Stoke Therapeutics an outperform vote while only 53.46% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEditas MedicineOutperform Votes31753.46% Underperform Votes27646.54% Stoke TherapeuticsOutperform Votes12176.58% Underperform Votes3723.42% Do insiders & institutionals have more ownership in EDIT or STOK? 71.9% of Editas Medicine shares are owned by institutional investors. 2.1% of Editas Medicine shares are owned by company insiders. Comparatively, 11.3% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is EDIT or STOK more profitable? Editas Medicine has a net margin of -340.96% compared to Stoke Therapeutics' net margin of -629.90%. Stoke Therapeutics' return on equity of -54.45% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-340.96% -80.13% -50.99% Stoke Therapeutics -629.90%-54.45%-40.77% Does the media prefer EDIT or STOK? In the previous week, Stoke Therapeutics had 25 more articles in the media than Editas Medicine. MarketBeat recorded 35 mentions for Stoke Therapeutics and 10 mentions for Editas Medicine. Stoke Therapeutics' average media sentiment score of 0.68 beat Editas Medicine's score of 0.65 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStoke Therapeutics beats Editas Medicine on 11 of the 18 factors compared between the two stocks. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.57M$2.93B$5.37B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.5930.5026.8419.71Price / Sales3.50400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book0.353.286.794.50Net Income-$153.22M-$72.17M$3.23B$248.18M7 Day Performance7.53%2.96%1.53%0.20%1 Month Performance-3.85%3.25%10.05%12.37%1 Year Performance-75.08%-28.29%16.71%7.04% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.2669 of 5 stars$1.58+5.0%$5.36+240.5%-72.8%$130.93M$35.84M-0.61230STOKStoke Therapeutics3.482 of 5 stars$9.00-6.8%$25.60+184.4%-38.2%$491.37M$36.56M-4.29100Analyst RevisionRLAYRelay Therapeutics3.1734 of 5 stars$2.82-9.3%$17.67+526.5%-62.2%$483.48M$7.68M-1.08330Positive NewsTSHATaysha Gene Therapies2.8673 of 5 stars$2.35+1.3%$6.63+181.9%+0.0%$481.88M$8.33M3.73180Earnings ReportAnalyst RevisionMNMDMind Medicine (MindMed)2.2658 of 5 stars$6.37-1.2%$25.11+294.2%-16.8%$480.09MN/A-2.8240Positive NewsUPBUpstream Bio2.0963 of 5 stars$8.83-7.1%$56.50+539.9%N/A$475.00M$2.30M0.0038News CoverageDNAGinkgo Bioworks1.1156 of 5 stars$8.18-1.6%$4.58-44.1%N/A$474.72M$237.42M-0.63640Positive NewsURGNUroGen Pharma4.0387 of 5 stars$10.10-9.3%$32.86+225.3%-68.6%$465.68M$90.40M-3.21200Trending NewsAnalyst ForecastETONEton Pharmaceuticals2.3952 of 5 stars$17.34-0.1%$27.67+59.6%+463.8%$465.02M$39.01M-78.8220Positive NewsAnalyst RevisionARVNArvinas3.7292 of 5 stars$6.23-4.4%$20.91+235.7%-82.0%$454.73M$426.90M-2.25420CGEMCullinan Therapeutics2.3133 of 5 stars$7.64-3.4%$32.00+318.8%-66.0%$450.88MN/A-2.6930High Trading Volume Related Companies and Tools Related Companies Stoke Therapeutics Competitors Relay Therapeutics Competitors Taysha Gene Therapies Competitors Mind Medicine (MindMed) Competitors Upstream Bio Competitors Ginkgo Bioworks Competitors UroGen Pharma Competitors Eton Pharmaceuticals Competitors Arvinas Competitors Cullinan Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDIT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDIT Stock Free EDIT Stock Alerts